Molina Healthcare's Third Quarter 2026 Earnings Conference Call - MOLINA HEALTHCARE INC

Financial Performance:

• Reported third-quarter 2026 premium revenue of $10.5 billion and adjusted earnings per share (EPS) of $0.89.
• Consolidated Medical Cost Ratio (MCR) was 92.9%; adjusted pre-tax margin was 0.6% for the quarter and 1.1% year-to-date.
• Segment MCRs were 93% for Medicaid, 93% for Medicare, and 92.5% for the Marketplace.
• Operating cash flow for the first nine months of 2026 totaled $629 million, with subsidiary dividends of $185 million harvested in Q3.
• Parent company cash balance ended the quarter at approximately $600 million; net debt-to-capital ratio was 45%.
• Claims payable ratio stood at 44% at quarter-end.

Guidance and Future Outlook:

• Reaffirmed full-year 2026 premium revenue guidance of approximately $42 billion and adjusted EPS guidance of at least $5.25.
• Increased full-year 2026 rate outlook to 4.5% (from 4%) and medical cost trend to 5.5% (from 5%) due to off-cycle updates and elevated utilization.
• Preliminary 2027 premium revenue outlook is at least $45 billion, down from prior expectations due to delays in Georgia and Texas RFP awards.
• Preliminary 2027 EPS building blocks sum to over $9.50, driven by known items including embedded earnings and operating leverage, excluding legacy margin recovery.
• Projected 2027 Medicaid rates of approximately 6% and trend of 5.5% to 6.0%, with potential for flat MCR or margin improvement.
• Full-year 2026 MCR guidance remains 92.6% (consolidated) and G&A guidance at 6.4%.

Business Segments and Product Lines:

• Medicaid: Expected to contribute $5.75/share for 2026 with a 1.6% legacy pre-tax margin; membership down 4.5% YTD, tracking a 6% full-year decline.
• Medicare: Duals business performing strongly (1.4% pre-tax margin, $1.25/share contribution); MAPD business expected to lose $1.00/share and is being exited in 2027.
• Marketplace: Expected to report a $0.75/share loss for 2026 due to reduced footprint and pricing strategy; planned to reduce operations to seven states in 2027.
• New Contracts: The $6 billion Florida CMS contract (115,000 members) is off to a strong start; projected to be a $1.50/share drag in 2026 but reach break-even in 2027.
• RFP Pipeline: Submitted bids for Texas Star Kids, Missouri, Arizona, and Indiana; $26 billion in RFPs remain outstanding against a $90 billion opportunity.

Market and Competitive Landscape:

• States are increasingly incorporating recent medical claims data and prospective acuity shifts (e.g., work requirements) into rate baselines.
• Medicaid rate environment appears to be recovering; most states are slightly underfunded, with January 1, 2027, rate increases averaging ~7% on the known cohort.
• Market trends indicate a stabilization in the imbalance between rates and medical cost trends, suggesting margins may have reached a trough.
• Competition remains active, with 80% of states leaning toward enrollment-promoting policies regarding work requirements and exemptions.

Risks and Challenges:

• RFP Delays: Judicial proceedings in Georgia and Texas are causing delays in contract implementation, deferring $1.3 billion of premium.
• Membership Attrition: Federal work requirements and biannual re-verifications are projected to cause a 6% membership decline in 2027, with a 1% impact on medical trend from acuity shifts.
• Medical Costs: Elevated utilization and acuity shifts in LTSS (Long-Term Services and Supports) and behavioral health continue to pressure margins.
• Operational Complexity: High-acuity populations in new contracts (e.g., Florida) require significant one-time reserve investments, impacting near-term earnings.

Management Commentary and Tone:

• Management expressed confidence in the stability of Medicaid margins and the "turn" in the industry cycle, citing rate improvements and trend plateauing.
• Tone was optimistic regarding the 2027 outlook, with the belief that rates will capture trend and drive margin expansion.
• Joe Zabreski (CEO) emphasized that the Medicaid margin trough is likely behind them, supported by state willingness to adjust rates for acuity.
• Mark Gein (CFO) noted that the embedded earnings of $9/share remain unchanged but adjusted the 2027 realization to $4/share due to timing delays.

Analyst Questions and Answers:

• Q3 Performance: Clarified that excluding the Florida CMS contract drag, underlying Medicaid MLR improved sequentially by 50-60 basis points due to rate updates and seasonality.
• Work Requirements: Confirmed that Nebraska's early implementation shows moderate impact (90% renewal rate), with 80% of states leaning toward liberal interpretations (ex parte, self-attestation) to limit disenrollment.
• Florida Contract: Detailed the path to break-even: Q4 includes a 99% MLR and 5% pre-tax loss due to one-time reserves; 500 bps of improvement needed in 2027, primarily via G&A leverage and MCR stabilization.
• Trend Assumptions: Explained that the 5.5% trend guidance is a "jumping-off point" for 2027, composed of 4.5% core trend and 1% acuity shift, with 50 bps of added conservatism.
• California Eligibility: Stated that asset limit changes are fully modeled in outlooks; disproportionate membership declines are expected in CA but have limited MLR impact.

Other Key Points:

• Embedded Earnings: Components for 2027 include $1.50 from current-year Florida losses (non-recurring in 2027), $1.00 from MAPD losses (non-recurring), and $1.50 from operating leverage; total 2027 harvest is $4.00/share.
• Reserve Adequacy: Management remains confident in the actuarial process and reserve position, noting no material prior period development impacts in Q3.
• 2029 Targets: Reiterated long-term goal of achieving 2.5% Medicaid pre-tax margins by 2029 (90 bps improvement from current levels).
• Calendar: Final 2027 guidance, including specific MCR assumptions, will be released in February.